ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

ODAC Recommends Approval of Gemcitabine For Pancreatic Cancer

August 4, 1995

Orders Still Accepted For 20th Anniversary Special Publication

July 19, 1991

Mammography Controversy Continues: Task Force Alters Web Site To Clarify Recommendation On Mammography

December 4, 2009

Advisors Approve $50 Million NCI Effort To Attack Cancer On a Molecular Level

July 2, 1999

Senate Subcommittee Gives NCI 41.397 Billion for FY ‘87

August 8, 1986

FDA Proposes Office For Patients With Life Threatening Disease

November 13, 1992